We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Takeda Products Ireland Ltd

First Floor, 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
Telephone: +353 1 642 0021
Fax: +353 1 642 0020
Medical Information Direct Line: 1800 937970
Medical Information e-mail: DSO-UK@takeda.com
Medical Information Facsimile: +44 (0)1628 526 617
Patient Information Leaflet last updated on medicines.ie: 17/03/2017
PIL Instanyl 50, 100 and 200 mcg/dose nasal spray

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17/03/2017 and displayed until Current
Reasons for adding or updating:
  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision
Updated on 24/01/2017 and displayed until 17/03/2017
Reasons for adding or updating:
  • Change to section 6 - manufacturer
Updated on 30/03/2015 and displayed until 24/01/2017
Reasons for adding or updating:
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision
Updated on 02/03/2015 and displayed until 30/03/2015
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 17/09/2014 and displayed until 02/03/2015
Reasons for adding or updating:
  • Change to date of revision
  • Change to marketing authorisation holder
Updated on 12/05/2014 and displayed until 17/09/2014
Reasons for adding or updating:
  • Change to date of revision
  • Change to improve clarity and readability
Updated on 17/04/2014 and displayed until 12/05/2014
Reasons for adding or updating:
  • Change of contraindications
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 13/12/2013 and displayed until 17/04/2014
Reasons for adding or updating:
  • Change of manufacturer
Updated on 17/09/2013 and displayed until 13/12/2013
Reasons for adding or updating:
  • Change to marketing authorisation holder
Updated on 09/07/2013 and displayed until 17/09/2013
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 23/08/2012 and displayed until 09/07/2013
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 23/01/2012 and displayed until 23/08/2012
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 08/09/2011 and displayed until 23/01/2012
Reasons for adding or updating:
  • Change to side-effects
Updated on 25/08/2011 and displayed until 08/09/2011
Reasons for adding or updating:
  • Improved electronic presentation
Updated on 25/08/2011 and displayed until 25/08/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 27/08/2010 and displayed until 25/08/2011
Reasons for adding or updating:
  • Improved electronic presentation
Updated on 07/09/2009 and displayed until 27/08/2010
Reasons for adding or updating:
  • New PIL for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   fentanyl citrate